Tuberculosis

Tuberculosis
Tuberculosis, MTB, or TB (short for tubercle bacillus) is a common, and in many cases lethal, infectious disease caused by various strains of mycobacteria, usually Mycobacterium tuberculosis. Tuberculosis usually attacks the lungs but can also affect other parts of the body. It is spread through the air when people who have an active MTB infection cough, sneeze, or otherwise transmit their saliva through the air.
  • Scientists at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory and Stony Brook University have discovered a key difference in the way human cells and Mycobacterium tuberculosis bacteria, which cause TB, deliver unwanted proteins — marked with a "kiss of death" sequence — to their respective cellular recycling factories.
  • Researchers at the Institute for Genomic Biology at the University of Illinois have developed a way to harness the prodigious quantities of both genomic and metabolic data being generated with high-throughput genomics and other techniques.
  • The U.S. Food and Drug Administration today announced the award of $2.9 million to support six research projects that will help with the diagnosis, treatment, and prevention of tuberculosis (TB).
  • Kathleen Alexander, associate professor of wildlife in Virginia Tech's College of Natural Resources and Environment, has discovered a novel tuberculosis (TB) species in the Mycobacterium tuberculosis complex, a group of pathogens that have adapted by using mammals as hosts. It has been nearly two decades since a new organism was identified in this group; the majority were discovered in the early and mid 20th century.
  • While the U.S. has made great progress in the prevention and treatment of tuberculosis, the nation has become more susceptible to potential epidemics of multidrug-resistant tuberculosis (MDR-TB), according a study led by Johns Hopkins researchers.
  • New research has found that a genetic variant which reduces the chance of contracting diseases such as tuberculosis and leprosy is more prevalent in populations with long histories of urban living.
  • At an international gathering of TB vaccine researchers in Tallinn today, the Aeras Global TB Vaccine Foundation announced it will initiate a clinical trial of an investigational live recombinant tuberculosis vaccine to be led by researchers at Saint Louis University in St. Louis, Missouri, USA. The announcement was made at the Second Global Forum on TB Vaccine Development.
  • Elderly people might not benefit from some of the tuberculosis vaccines currently in development, recent research suggests.
  • An examination of a portion of the tuberculosis genome that responds to stress has allowed Rice University bioengineers Oleg Igoshin and Abhinav Tiwari to zero in on a network of genes that may "switch" the disease into dormancy.
  • Tuberculosis, or TB, is a dreaded contagious disease of the lungs and other organs. The causative agent, Mycobacterium tuberculosis (or M. tuberculosis), infects roughly a third of the world's population and one-in-ten to one-in-twenty of the infected population becomes sick or infectious at some point during their lifetime.
  • One third of the world's population is infected with Mycobacterium tuberculosis (MTB), which leads to tuberculosis (TB), a leading cause of death world-wide. A new discovery, led by a team of researchers from Case Western Reserve University School of Medicine, offers hope for new approaches to the prevention and treatment of TB. The team's discovery of a novel mechanism that may contribute to immune recognition of MTB is published in the September issue of Nature Structural and Molecular Biology.
  • WHAT: A molecular test designed to easily diagnose tuberculosis (TB) and detect a drug-resistant form of the bacterium that causes TB can provide much more specific, sensitive and rapid results than currently available TB diagnostics, according to a new study in the New England Journal of Medicine. In a test involving 1,730 patients with suspected drug-sensitive or multidrug-resistant pulmonary TB, the Xpert MTB/RIF TB test successfully identified 98 percent of all confirmed TB cases and 98 percent of patients with rifampin-resistant bacteria in less than two hours.
More